SCHEMBL31349463

SCHEMBL31349463

CC1(O)CC(n2cnc3cc(Br)cc(C(F)F)c32)C1

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.31
OPRL1 P41146 1/20 0.31
AR P10275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507209 0.86 AR (0.31) AR
SCHEMBL25316660 0.86 AR (0.31) AR
SCHEMBL26023925 0.86 AR (0.31) AR
SCHEMBL31698890 0.86 MEN1 (0.32)
SCHEMBL30507104 0.85 PRPS1 (0.38)
SCHEMBL25924928 0.85 PRPS1 (0.38)
SCHEMBL25317119 0.85 PRPS1 (0.38)
SCHEMBL25318420 0.84 MAP3K12 (0.32)
SCHEMBL30506911 0.84 MAP3K12 (0.32)
SCHEMBL25924578 0.84 MAP3K12 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed